832448

FLOOR AMENDMENT NO._____ BY: HERRERO

1 Amend H.B. No. 2 (House Committee Printing) as follows:
2 (1) On page 10, line 8, between "physician" and the
3 underlined semicolon, insert the following:
4 who:
5 (A) has the ability to:
6 (i) assess the duration of the pregnancy
7 accurately; and
8 (ii) diagnose an ectopic pregnancy;
9 (B) is capable of providing surgical
10 intervention in the case of an incomplete abortion or severe
11 bleeding or has made arrangements for another qualified physician
12 to provide the care described by this paragraph and has documented
13 those arrangements in the woman's medical record;
14 (C) is able to assure patient access to a medical
15 facility equipped to provide a blood transfusion and resuscitation;
16 and
17 (D) has read and understood the prescribing
18 information for the use of the abortion-inducing drug as provided
19 by the drug manufacturer in accordance with the requirements of the
20 United States Food and Drug Administration
21 (2) On page 10, strike lines 14-18 and substitute the
22 following:
23 (b) A person may provide, prescribe, or administer the
24 abortion-inducing drug:
25 (1) in the dosage amount prescribed by the clinical
26 management guidelines defined by the American Congress of
27 Obstetricians and Gynecologists Practice Bulletin as those
28 guidelines existed on January 1, 2013; or
29 (2) according to an evidence-based regimen.

1 (3) Strike page 10, line 24, through page 11, line 8, and
2 substitute the following:
3 (d) The physician who gives, sells, dispenses, administers,
4 provides, or prescribes an abortion-inducing drug shall:
5 (1) fully explain the procedure to the pregnant woman,
6 including:
7 (A) explaining whether the physician is using the
8 abortion-inducing drug:
9 (i) in accordance with the United States
10 Food and Drug Administration regimen described on the final printed
11 label;
12 (ii) in a dosage amount described by
13 Subsection (b)(1); or
14 (iii) in accordance with an evidence-based
15 regimen; and
16 (B) if using the dosage amount described by
17 Subsection (b)(1) or an evidence-based regimen:
18 (i) specifying that the dosage or regimen
19 used differs from the United States Food and Drug Administration
20 dosage or regimen described on the final printed label; and
21 (ii) providing detailed information on the
22 dosage or regimen being used;
23 (2) provide the pregnant woman with:
24 (A) the final printed label of the
25 abortion-inducing drug;
26 (B) a copy of the drug manufacturer's medication
27 guide for the abortion-inducing drug;
28 (C) a copy of the drug manufacturer's patient
29 agreement; and
30 (D) a telephone number by which the woman may
31 reach the physician, or other health care personnel employed by the

1 physician or by the facility at which the abortion was performed
2 with access to the woman's relevant medical records, 24 hours a day
3 to request assistance for any complications that arise from the
4 administration or use of the abortion-inducing drug or ask
5 health-related questions regarding the administration or use of the
6 abortion-inducing drug;
7 (3) obtain the patient's signature for and sign the
8 patient agreement described by Subdivision (2)(C); and
9 (4) record the drug manufacturer's package serial
10 number in the woman's medical record.